369 related articles for article (PubMed ID: 17631687)
41. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
[TBL] [Abstract][Full Text] [Related]
42. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.
Xia Y; Lei Q; Zhu Y; Ye T; Wang N; Li G; Shi X; Liu Y; Shao B; Yin T; Zhao L; Wu W; Song X; Xiong Y; Wei Y; Yu L
Cancer Lett; 2014 Dec; 355(2):297-309. PubMed ID: 25301449
[TBL] [Abstract][Full Text] [Related]
43. Solasodine, Isolated from
Fan Y; Li Z; Wu L; Lin F; Shao J; Ma X; Yao Y; Zhuang W; Wang Y
Drug Des Devel Ther; 2021; 15():1509-1519. PubMed ID: 33888977
[TBL] [Abstract][Full Text] [Related]
44. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.
Li YY; Wang YY; Taniguchi T; Kawakami T; Baba T; Ishibashi H; Mukaida N
Int J Cancer; 2010 Jul; 127(2):474-84. PubMed ID: 19921695
[TBL] [Abstract][Full Text] [Related]
45. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
46. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy.
Huang YS; Lu HL; Zhang LJ; Wu Z
Med Res Rev; 2014 May; 34(3):532-66. PubMed ID: 23922215
[TBL] [Abstract][Full Text] [Related]
47. Tenascin-C induces resistance to apoptosis in pancreatic cancer cell through activation of ERK/NF-κB pathway.
Shi M; He X; Wei W; Wang J; Zhang T; Shen X
Apoptosis; 2015 Jun; 20(6):843-57. PubMed ID: 25690319
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of bicyclic sigma receptor ligands with cytotoxic activity.
Geiger C; Zelenka C; Weigl M; Fröhlich R; Wibbeling B; Lehmkuhl K; Schepmann D; Grünert R; Bednarski PJ; Wünsch B
J Med Chem; 2007 Nov; 50(24):6144-53. PubMed ID: 17967001
[TBL] [Abstract][Full Text] [Related]
49. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
50. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
51. 7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands.
Banister SD; Rendina LM; Kassiou M
Bioorg Med Chem Lett; 2012 Jun; 22(12):4059-63. PubMed ID: 22607684
[TBL] [Abstract][Full Text] [Related]
52. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Tseng JF; Farnebo FA; Kisker O; Becker CM; Kuo CJ; Folkman J; Mulligan RC
Surgery; 2002 Nov; 132(5):857-65. PubMed ID: 12464871
[TBL] [Abstract][Full Text] [Related]
53. New analogs of SYA013 as sigma-2 ligands with anticancer activity.
Asong G; Zhu XY; Bricker B; Andey T; Amissah F; Lamango N; Ablordeppey SY
Bioorg Med Chem; 2019 Jun; 27(12):2629-2636. PubMed ID: 30987780
[TBL] [Abstract][Full Text] [Related]
54. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation.
Ludwig JM; Gai Y; Sun L; Xiang G; Zeng D; Kim HS
Mol Oncol; 2016 Aug; 10(7):1133-45. PubMed ID: 27262893
[TBL] [Abstract][Full Text] [Related]
55. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors.
Gil-Ad I; Shtaif B; Levkovitz Y; Dayag M; Zeldich E; Weizman A
J Mol Neurosci; 2004; 22(3):189-98. PubMed ID: 14997012
[TBL] [Abstract][Full Text] [Related]
56. Development and evaluation of a radiobromine-labeled sigma ligand for tumor imaging.
Ogawa K; Kanbara H; Kiyono Y; Kitamura Y; Kiwada T; Kozaka T; Kitamura M; Mori T; Shiba K; Odani A
Nucl Med Biol; 2013 May; 40(4):445-50. PubMed ID: 23528561
[TBL] [Abstract][Full Text] [Related]
57. Sigma-2 ligands induce tumour cell death by multiple signalling pathways.
Zeng C; Rothfuss J; Zhang J; Chu W; Vangveravong S; Tu Z; Pan F; Chang KC; Hotchkiss R; Mach RH
Br J Cancer; 2012 Feb; 106(4):693-701. PubMed ID: 22251921
[TBL] [Abstract][Full Text] [Related]
58. Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity.
Georgiadis MO; Karoutzou O; Foscolos AS; Papanastasiou I
Molecules; 2017 Aug; 22(9):. PubMed ID: 28841173
[TBL] [Abstract][Full Text] [Related]
59. In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS.
Waterhouse RN; Chang RC; Atuehene N; Collier TL
Synapse; 2007 Jul; 61(7):540-6. PubMed ID: 17447254
[TBL] [Abstract][Full Text] [Related]
60. New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents.
Chu W; Xu J; Zhou D; Zhang F; Jones LA; Wheeler KT; Mach RH
Bioorg Med Chem; 2009 Feb; 17(3):1222-31. PubMed ID: 19119012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
